GlassScriptPhysician profile
Samhitha Munugoti
NPI 1023630829
$338.11
in general payments reported to CMS, 2019-2025
12 companies · $338 in 2025
The $338 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $338.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48.04 | 2025 | Rybelsus, Ozempic, Wegovy |
| Corcept Therapeutics | $44.33 | 2025 | Korlym |
| Insulet Corporation | $42.60 | 2025 | Omnipod |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $32.24 | 2025 | Caplyta |
| Medtronic, INC. | $28.38 | 2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $26.00 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Dexcom, INC. | $23.89 | 2025 | Dexcom G6 Transmitter |
| Lundbeck LLC | $23.65 | 2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $19.84 | 2025 | Austedo Xr |
| Xeris Pharmaceuticals, INC. | $17.32 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $16.58 | 2025 | |
| Exact Sciences Corporation | $15.24 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samhitha Munugoti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.